JY
RYTM icon

Jeff Yass’s Rhythm Pharmaceuticals RYTM Stock Holding History

Jeff Yass’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11M Buy
99,000
+16,100
+19% +$1.46M ﹤0.01% 3250
2026
Q1 		$7.21M Sell
82,900
-129,900
-61% -$12.6M ﹤0.01% 3606
2025
Q4 		$22.8M Sell
212,800
-46,800
-18% -$4.96M ﹤0.01% 2068
2025
Q3 		$26.2M Buy
259,600
+199,400
+331% +$18.5M ﹤0.01% 1918
2025
Q2 		$3.8M Sell
60,200
-28,600
-32% -$1.75M ﹤0.01% 4496
2025
Q1 		$4.7M Sell
88,800
-26,500
-23% -$1.47M ﹤0.01% 3769
2024
Q4 		$6.45M Sell
115,300
-117,300
-50% -$6.48M ﹤0.01% 3223
2024
Q3 		$12.2M Buy
232,600
+139,100
+149% +$6.67M ﹤0.01% 2363
2024
Q2 		$3.84M Sell
93,500
-169,200
-64% -$6.75M ﹤0.01% 3879
2024
Q1 		$11.4M Sell
262,700
-8,300
-3% -$363K ﹤0.01% 2433
2023
Q4 		$12.5M Buy
271,000
+219,600
+427% +$6.93M ﹤0.01% 2355
2023
Q3 		$1.18M Buy
51,400
+16,600
+48% +$372K ﹤0.01% 6268
2023
Q2 		$574K Sell
34,800
-70,300
-67% -$1.27M ﹤0.01% 7985
2023
Q1 		$1.87M Buy
105,100
+29,600
+39% +$743K ﹤0.01% 5276
2022
Q4 		$2.2M Sell
75,500
-202,700
-73% -$5.21M ﹤0.01% 4523
2022
Q3 		$6.82M Buy
278,200
+168,500
+154% +$3.13M ﹤0.01% 2693
2022
Q2 		$455K Buy
109,700
+5,200
+5% +$28.5K ﹤0.01% 8514
2022
Q1 		$1.2M Buy
+104,500
New +$917K ﹤0.01% 6645
2021
Q1 		– Sell
-56,500
Closed -$1.68M – 12773
2020
Q4 		$1.68M Buy
56,500
+46,800
+482% +$1.19M ﹤0.01% 5482
2020
Q3 		$210K Buy
+9,700
New +$222K ﹤0.01% 9370
2019
Q4 		– Sell
-9,900
Closed -$214K – 10495
2019
Q3 		$214K Buy
+9,900
New +$212K ﹤0.01% 8970

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jeff Yass's RYTM Position: Q2 2026 in Review

Jeff Yass reduced its Rhythm Pharmaceuticals (RYTM) stake by 91% in Q2 2026, selling an estimated $4.2M and leaving 4,372 shares worth $485K. The position accounts for ﹤0.01% of the portfolio, ranked #9990.

Jeff Yass first reported a position in RYTM in Q2 2019 and has held it in 28 quarters since. The position peaked at $20.2M in Q4 2022. 300 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Jeff Yass held 4,372 shares of Rhythm Pharmaceuticals worth $485K as of Q2 2026.
  • Jeff Yass sold 46,412 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $4.2M.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #9990 holding.
  • Jeff Yass first reported a position in Rhythm Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
  • Jeff Yass's Rhythm Pharmaceuticals position peaked at $20.2M in Q4 2022.
  • 300 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.